Sialic acid accelerates the electrophoretic velocity of injured dorsal root ganglion neurons

Peripheral nerve injury has been shown to result in ectopic spontaneous discharges on soma and injured sites of sensory neurons, thereby inducing neuropathic pain. With the increase of membrane proteins on soma and injured site neurons, the negatively charged sialic acids bind to the external domains of membrane proteins, resulting in an increase of this charge. We therefore speculate that the electrophoretic velocity of injured neurons may be faster than non-injured neurons. The present study established rat models of neuropathic pain via chronic constriction injury. Results of the cell electrophoresis test revealed that the electrophoretic velocity of injured neuronal cells was faster than that of non-injured （control） cells. We then treated cells with divalent cations of Ca2＋ and organic compounds with positive charges, polylysine to counteract the negatively charged sialic acids, or neuraminidase to specifically remove sialic acids from the membrane surface of injured neurons. All three treatments significantly reduced the electrophoretic velocity of injured neuronal cells. These findings suggest that enhanced sialic acids on injured neurons may accelerate the electrophoretic velocity of injured neurons.

Effect of dexamethasone on intelligence and hearing in preterm infants: a meta-analysis

OBJECTIVE： A meta-analysis of published randomized controlled trials investigating the long- term effect of dexamethasone on the nervous system of preterm infants. DATA SOURCES： Online literature retrieval was conducted using The Cochrane Library （from January 1993 to June 2013）, EMBASE （from January 1980 to June 2013）, MEDLINE （from Janu- ary 1963 to June 2013）, OVID （from January 1993 to June 2013）, Springer （from January 1994 to June 2013） and Chinese Academic Journal Full-text Database （from January 1994 to June 2013）. Key words were preterm infants and dexamethasone in English and Chinese. STUDY SELECTION： Selected studies were randomized controlled trials assessing the effect of intravenous dexamethasone in preterm infants. The quality of the included papers was evaluated and those without the development of the nervous system and animal experiments were exclud- ed. Quality assessment was performed through bias risk evaluation in accordance with Cochrane Handbook 5.1.0 software in the Cochrane Collaboration. The homogeneous studies were analyzed and compared using Revman 5.2.6 software, and then effect model was selected and analyzed. Those papers failed to be included in the meta-analysis were subjected to descriptive analysis. MAIN OUTCOME MEASURES： Nervous system injury in preterm infants. RESULTS： Ten randomized controlled trials were screened, involving 1,038 subjects. Among them 512 cases received dexamethasone treatment while 526 cases served as placebo control group and blank control group. Meta-analysis results showed that the incidence of cerebral palsy, visual im- pairment and hearing loss in preterm infants after dexamethasone treatment within 7 days after birth was similar to that in the control group （RR = 1.47, 95%CI： 0.97-2.21; RR = 1.46, 95%CI： 0.97-2.20; RR = 0.80, 95%CI： 0.54-1.18; P 〉 0.05）, but intelligence quotient was significantly de- creased compared with the control group （MD = -3.55, 95%CI： -6.59 to -0.51; P = 0.02）. Prete rm infants treated with dexamethasone 7 days after birth demonstrated an incidence of cerebral palsy and visual impairment, and changes in intelligence quotient similar to those in the control group （RR = 1.26, 95%CI： 0.89-1.79; RR = 1.37, 95%CI： 0.73-2.59; RR = 0.53, 95%CI： 0.32-0.89; RR = 1.66, 95%CI： -4.7 to 8.01; P 〉 0.05）. However, the incidence of hearing loss was significantly increased compared with that in the control group （RR = 0.53, 95%CI： 0.32-0.89; P = 0.02）. CONCLUSION： Dexamethasone may affect the intelligence of preterm infants in the early stages after birth, but may lead to hearing impairment at later stages after birth. More reliable conclusions should be made through large-size, multi-center, well-designed randomized controlled trials.

SYNTHETIC AND CATALYTIC PROPERTY STUDIES ON SILICA SUPPORTED BIS-(ACETYLACETONATO) COBALT(Ⅱ) COMPLEXES^(**)

This paper reports mainly the preparation of silica supported acetylacetone ligands and their cobalt complexes, the characterization of their chemical structure, and the evaluation of their catalytic activity in the reaction for the preparation of ethers directly from alkanols and benzyl chloride. The results indicate that those silica supported β-diketone cobalt complexes (SACO) not only can simplify the reaction procedure of the ether preparation but also show a much higher catalytic activity in comparison with other homogeneous catalysts. In addition, SACO can be recovered and reused although their catalytic activity descend gradually as a result of the decrease in their cobalt content.

Drinking Water as Iron Carrier for the Prevention of Iron Deficiency Anemia:The Brazilian Experience

On a global base, estimated 2 billion people are iron deficient and/or anemic with small children and child bearing age most likely to be the ones affected. These high levels of world anemia prevalence have been maintained and even growing in spite of the global and national food fortification programmes carried out in several places. These have been based on the iron fortification of local foods. In Brazil a wheat flour iron fortification program has been going on for several years and the anemia prevalence has been going on as a still large public health problem. We started since the nineties and in several under five day care centers, in various part of Brazil a new program using drinking water as the iron carrier for the prevention of iron deficiency anemia. It was shown through several studies in different places in Brazil that drinking water being available everywhere, daily consumed by everyone, children, adults and old people have shown to be effective for the prevention of iron anemia. Iron salts are low-priced, water soluble, effective, easily and locally prepared, should be known and accepted as a rational, practical and effective locally community preventive solution for iron anemia, still a great problem of our developing and underdeveloped countries of the world.

An integrative Tai Chi program for patients with breast cancer undergoing cancer therapy:study protocol for a randomized controlled feasibility study

Background： Breast cancer patients experience various side effects during cancer therapy, often resulting in reduced quality of life and poor adherence to treatment. A limited range of proven interventions has been developed to target such side effects. While Tai Chi offers benefits for the health and well-being of breast cancer survivors, the effectiveness of Tai Chi across the treatment continuum has not been evalu- ated. Improved patient education and support has been suggested as a priority for breast cancer care. This pilot study assesses the feasibility of a randomized controlled trial （RCT） to evaluate the effectiveness of ＂an integrative Tai Chi＂ （ANITA） program for breast cancer patients undergoing cancer therapy. Methods/design： This is a single-centre, two-arm feasibility RCT. Twenty-four patients with breast cancer who have undergone surgical treatment will be recruited from the Dunedin Hospital （New Zealand） over a 12-month period （from August 2017 to July 2018）. Subject to informed consent, patients will be ran- domized to receive standard cancer treatment alone or standard cancer treatment plus the ANITA pro- gram, consisting of peer support, health education, and Tai Chi Ruler exercise. The program runs alongside the patient＇s adjuvant cancer therapy, which may include chemotherapy, radiation therapy, antibody treatment, and/or antihormonal therapy. Analysis in this study will focus on process evaluation of participant recruitment, retention, treatment fidelity, acceptability of the program, and occurrence of adverse events. Clinical outcomes （i.e., fatigue, sleep quality, anxiety and depression and quality of life） will be assessed at baseline, and at 12 weeks and 24 weeks post-randomization. Discussion： Outcomes from this study will inform the feasibility and methodology for a future fully- powered RCT.